Mechanism of antilipolytic effects of cardiac glycosides.
D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D002087:Butyrates / Q000494:pharmacology; D002301:Cardiac Glycosides / Q000494:pharmacology*; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D000242:Cyclic AMP / Q000494:pharmacology; D004074:Digitoxin / Q000494:pharmacology; D004822:Epididymis / Q000187:drug effects / Q000378:metabolism; D004952:Esters; D005990:Glycerol / Q000378:metabolism; D066298:In Vitro Techniques; D050356:Lipid Metabolism; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D010042:Ouabain / Q000494:pharmacology; D010744:Phosphoric Monoester Hydrolases / Q000037:antagonists & inhibitors; D011188:Potassium / Q000494:pharmacology; D051381:Rats; D013328:Strophanthins / Q000494:pharmacology; D013806:Theophylline / Q000494:pharmacology; D014316:Tritium
D002087:Butyrates; D002301:Cardiac Glycosides; D004952:Esters; D013328:Strophanthins; D014316:Tritium; D010042:Ouabain; D013806:Theophylline; D000242:Cyclic AMP; D004074:Digitoxin; D010744:Phosphoric Monoester Hydrolases; D005990:Glycerol; D011188:Potassium; D009638:Norepinephrine